SEC Filing Details

We are a clinical-stage biopharmaceutical company leveraging our proprietary next-generation, non-viral gene engineering technologies to create life-saving cell and gene therapies for patients with high unmet medical need.

SEC Filing Details

Document Details

Form
424B5
Filing Date
Aug 3, 2022
Document Date
Aug 3, 2022
Form Description
Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3
Filing Group
Registration Statements
Company
Poseida Therapeutics, Inc.
Issuer
Poseida Therapeutics, Inc.